Related Experiment Videos
Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex
Jerry A Shields1, Ralph C Eagle, Carol L Shields
1Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Transactions of the American Ophthalmological Society
|March 8, 2005
Summary
Retinal astrocytic tumors in tuberous sclerosis complex (TSC) can grow aggressively, leading to vision loss and necessitating eye removal. Regular eye exams are crucial for early detection and management of these rare growths.
Area of Science:
- Ophthalmology
- Oncology
- Genetics
Context:
- Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the growth of hamartomas in multiple organs.
- Retinal astrocytic hamartomas are a known ocular manifestation of TSC, typically presenting as stationary lesions.
- This study focuses on a rare subset of TSC-associated retinal astrocytic tumors exhibiting aggressive, progressive growth.
Purpose:
- To describe the clinical and histopathologic features of rapidly growing retinal astrocytic tumors in four patients with TSC.
- To highlight the potential for severe ocular complications, including blindness and the need for enucleation, in these cases.
Summary:
- Four children with TSC developed enlarging retinal neoplasms causing exudative retinal detachment and neovascular glaucoma, requiring enucleation.
- Histopathology revealed giant cell astrocytomas, similar to brain subependymal giant cell astrocytomas in TSC, with positive glial fibrillary acidic protein and neuron-specific enolase.
- Tumors mimicked retinoblastoma clinically but were diagnosed as astrocytic hamartomas based on systemic and ocular TSC findings.
Impact:
- Demonstrates that while typically stationary, retinal astrocytic lesions in TSC can grow aggressively, leading to significant ocular morbidity.
- Emphasizes the critical need for vigilant, serial ophthalmic evaluations in patients with TSC and retinal astrocytic hamartomas.
- Informs clinical management strategies for TSC patients, underscoring the importance of monitoring for potentially vision-threatening ocular tumors.